The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus-Reference-Cited by-同舟云学术

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Published:2016-12-07 Issue:5 Volume:8 Page:7598-7613
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Vázquez Ramiro¹,Riveiro María E.²,Astorgues-Xerri Lucile²,Odore Elodie²³,Rezai Keyvan³,Erba Eugenio¹,Panini Nicolò¹,Rinaldi Andrea⁴,Kwee Ivo⁴⁵⁶,Beltrame Luca¹,Bekradda Mohamed²,Cvitkovic Esteban²⁷,Bertoni Francesco⁴⁸,Frapolli Roberta¹,D'Incalci Maurizio¹

Affiliation:

1. Laboratory of Anti-tumor Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

2. Oncology Therapeutic Development, Clichy, France

3. Radiopharmacology Department, Curie Institute-René Huguenin Hospital, Saint Cloud, France

4. Institute of Oncology Research (IOR), Bellinzona, Switzerland

5. Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland

6. Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland

7. Oncoethix GmbH (formerly Oncoethix SA), Merck Sharp and Dohme Corp., Switzerland

8. Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the Molecules in EMT: A Potential Therapeutic Opportunity in Breast Cancer;Current Molecular Medicine;2024-08-19

2. Beyond the Usual Suspects: Examining the Role of Understudied Histone Variants in Breast Cancer;International Journal of Molecular Sciences;2024-06-20

3. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment;Pharmacological Research;2024-06

4. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis;European Journal of Medicinal Chemistry;2024-02

5. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression;Cancer Research;2024-01-19